Skip to main content
. 2021 Apr 9;14(4):1390–1402. doi: 10.1111/cts.12993

Table 3.

Subgroup analysis of treatment‐induced changes in thyroid antibody and TSH titers by basal Se levels or thyroid function status

Se‐treated group Control group p value Interaction p value
N Total 43 47
Outcomes Subgroup
ΔTPOAb, IU/ml Se level 0.113

S1 < 80 μg/L

(n = 49)

−37.1 (n = 25)

(−121.7, 0.0)

2.9 (n = 24)

(−19.6, 33.7)

0.001

S2 ≥ 80 μg/L

(n = 41)

−6.45 (n = 18)

(−50.9, 0.0)

−1.2 (n = 23)

(−18.1, 2.5)

0.180
Thyroid function 0.054
EHT (n = 61)

−6.8 (n = 27)

(−47.1, 0.0)

−0.5 (n = 34)

(−18.8, 32.6)

0.077
SHT (n = 29)

−86.5 (n = 16)

(−195.7, −28.3)

0.0 (n = 13)

(−12.7, 12.8)

0.003
ΔTGAb, IU/ml Se level 0.687

S1 <80 μg/L

(n = 49)

−43.3 (n = 25)

(−114.4, −3.4)

30.5 (n = 24)

(−18.8, 73.4)

0.002

S2 ≥ 80 μg/L

(n = 41)

−56.5 (n = 18)

(−375.1, 22.7)

12.7 (n = 23)

(−36.5, 95.6)

0.098
Thyroid function 0.853
EHT (n = 61)

−62.3 (n = 27)

(−181.8, −4.2)

18.1 (n = 34)

(−32.9, 77.3)

0.004
SHT (n = 29)

−21.3 (n = 16)

(−126.1, 27.7)

26.6 (n = 13)

(−5.3, 112.8)

0.039
ΔTSH, mIU/L Se level 0.116

S1 < 80 μg/L

(n = 49)

−0.63 (n = 25)

(−2.83, 0.27)

0.49 (n = 24)

(1.11, 0.12)

0.001

S2 ≥ 80 μg/L

(n = 41)

−0.01 (n = 18)

(−0.67, 0.52)

0.29 (n = 23)

(−0.91, 1.74)

0.293
Thyroid function 0.003
EHT (n = 61)

0.01 (n = 27)

(−0.61, 0.68)

0.38 (n = 34)

(−0.05, 1.06)

0.079
SHT (n = 29)

−2.5 (n = 16)

(−4.02, −0.28)

1.91 (n = 13)

(−1.36, 2.76)

0.002

Δ = value after treatment − baseline value.

Abbreviations: EHT, euthyroid Hashimoto thyroiditis; S1: Se <80 μg/L; S2: >80 μg/L; Se, selenium; SHT, subclinical Hashimoto thyroiditis; TgAb, antithyroglobulin antibodies; TPOAb, antithyroid peroxidase antibodies; TSH, thyroid stimulating hormone.